ENDPOINTS NEWS1h
J&J takes 340B fight with fed­er­al gov­ern­ment to court
John­son & John­son is su­ing the fed­er­al gov­ern­ment over its re­buke of the com­pa­ny’s al­ter­na­tive mod­el for 340B ...
ENDPOINTS NEWS1h
Adap­ti­m­mune's sec­ond T cell re­cep­tor cell ther­a­py for rare sar­co­mas pass­es piv­otal test
Adap­ti­m­mune an­nounced Wednes­day that its ex­per­i­men­tal cell ther­a­py based on T cell re­cep­tors shrank tu­mors by ...
ENDPOINTS NEWS2h
Pri­ma­ry care uni­corn start­up For­ward Health shuts down
Forward Health, a San Francisco-based primary care startup offering $150 monthly subscription services through ...
ENDPOINTS NEWS2h
Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs
Just sev­en months af­ter un­veil­ing with $290 mil­lion, obe­si­ty biotech Met­sera is back with an­oth­er $215 mil­lion.
ENDPOINTS NEWS3h
Ot­su­ka and ICU Med­ical forge IV man­u­fac­tur­ing net­work to sup­ply the US
Otsuka Pharmaceutical Factory and ICU Medical have formed a $200 million joint venture to bolster the US IV product supply ...
ENDPOINTS NEWS5h
TRexBio rais­es $84M to take in-house im­mune pro­gram in­to the clin­ic
TRexBio secured $84 million Series B funding, led by Delos Capital with Eli Lilly and Johnson & Johnson participating, to ...
ENDPOINTS NEWS5h
Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug
A lot of Am­gen’s fu­ture rides on its ex­per­i­men­tal obe­si­ty med­i­cine Mar­i­Tide. At least in the minds of in­vestors.
ENDPOINTS NEWS5h
New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug
BioNTech is acquiring Chinese biotech Biotheus for $800 million upfront plus $150 million in milestones, gaining multiple ...
ENDPOINTS NEWS5h
Ex­clu­sive: Flag­ship names two CEO-part­ners to lead Va­lo Health, Apri­ori Bio
Flag­ship Pi­o­neer­ing has ap­point­ed two new CEO-part­ners to ad­vise its port­fo­lio com­pa­nies and help steer its ...
ENDPOINTS NEWS6h
Sy­ros' shares plum­met as blood can­cer drug fails again
Sy­ros Phar­ma­ceu­ti­cals’ share price nose­dived af­ter its last drug can­di­date flunked a tri­al in hema­to­log­i­cal ...
ENDPOINTS NEWS20h
Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports
Pfizer, reportedly working with Goldman Sachs, is considering selling its hospital drugs unit while facing pressure from ...
ENDPOINTS NEWS21h
As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion
AstraZeneca CEO Pascal Soriot affirms commitment to China despite investigation involving China president Leon Wang and other employees. Wang, who reported directly to Soriot, and former AstraZeneca ...